Parp inhibitors in prostate cancer: Practical guidance for busy clinicians

INIS

• patients 100%
• therapy 100%
• cancer 80%
• prostate 80%
• diseases 60%
• mutations 60%
• biological markers 60%
• metastases 60%
• adp 60%
• ribose 60%
• tissues 40%
• dna 40%
• genes 40%
• food and drug administration 40%
• data 20%
• radiations 20%
• comparative evaluations 20%
• repair 20%
• management 20%
• men 20%
• biopsy 20%
• plasma 20%
• androgens 20%
• yields 20%
• gold 20%
• gene recombination 20%
• castration 20%
• pies 20%

Medicine and Dentistry

• Patient 100%
• Prostate Cancer 80%
• Olaparib 80%
• Biological Marker 60%
• Poly(adenosine Diphosphate Ribose) 60%
• Diseases 40%
• Combination Therapy 40%
• BRCA2 40%
• Abiraterone 40%
• Enzalutamide 40%
• Rucaparib 40%
• Tissues 40%
• Targeted Therapy 40%
• Overall Survival 20%
• Disease Exacerbation 20%
• Monotherapy 20%
• BRCA1 20%
• Gene Repair 20%
• Castration 20%
• Gene 20%
• Homologous Recombination 20%
• Recombination Repair 20%
• Androgen Deprivation Therapy 20%
• Man 20%
• Clinician 20%
• Biopsy 20%
• Plasma 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 80%
• Olaparib 80%
• Biological Marker 60%
• Poly(adenosine Diphosphate Ribose) 60%
• Diseases 40%
• DNA 40%
• Abiraterone 40%
• Enzalutamide 40%
• Rucaparib 40%
• Radiation 40%
• Overall Survival 20%
• Disease Exacerbation 20%
• Monotherapy 20%